Should You Buy AbbVie Inc (ABBV) Today? Analysis, Price Targets, and 2026 Outlook.
Analysis Updated At
2026/01/28
ABBV is a good buy right now for a beginner long-term investor with $50k–$100k. The stock is in a constructive uptrend (bullish MACD, RSI not yet overbought), options positioning is skewed bullish (put/call ratios below 1), and the company’s shareholder-return story (dividend growth, ~3.2% yield) remains a strong long-term support. While Congress activity is notably one-sided selling and the last reported quarter showed a sharp EPS/net income drop, the market focus for ABBV remains on continued revenue growth and the durability of Skyrizi/Rinvoq—supported by multiple recent bullish price targets. Buying now around ~$223 (just under first resistance) is still reasonable for long-term accumulation rather than trying to time a perfect pullback.
Technical Analysis
Price/Trend (pre-market): ~$222.71 (-0.54%), sitting just below R1 (224.93) and above the pivot (218.47), which suggests an ongoing uptrend but with near-term overhead resistance.
Momentum: MACD histogram is +0.25 and expanding (bullish momentum building). RSI(6)=66.0 (upper-neutral; positive momentum without a clear overbought reading yet).
Moving averages: Converging MAs point to consolidation after an advance; typically a “pause” zone where a breakout above ~224.9 can extend the move.
Key levels: Support: 218.47 (pivot), then 212.02. Resistance: 224.93, then 228.92.
Pattern-based forward bias (statistical): +0.85% over the next week and +3.89% over the next month (mildly bullish).
Intellectia Proprietary Trading Signals
- [AI Stock Picker](module://ai_stock_pick): No signal on given stock today.
- [SwingMax](module://swingmax): No signal on given stock today.